Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by kareadon Nov 14, 2009 5:14pm

159 Views

Post# 16487489

RE: RE: RE: RE: RE: Karead, you are missing the po

Lol...yep, that's it.

In all seriousness duskw, your version is not that far from the truth. However I finally learned my lesson. And, I may well be back, but it would be quite a bit before the $3-$4 range.

Can one of you please reference one or more of my posts where I have "bashed" the company...?

Bullboard Posts

How a truck transportation and logistics company leverages acquisitions and technology